Matterhorn Biosciences Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Out of Business

  • Employees
  • 41

Employees

  • Latest Deal Type
  • Liquidation

Matterhorn Biosciences General Information

Description

Developer of M-TCR cell therapies designed to focus on the discovery of cellular therapies targeting the MR1 molecule. The company's therapies offer will develop treatments based on T cells that target metabolites, like sugars, present in cancer cells by a molecule called MR1 along with a library of T-cell receptors that can be attached to MR1T cells that recognize different metabolites, enabling physicians and doctors to recognize and kill a wide range of tumors of various tissue origins.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • Aeschenvorstadt 36
  • 4051 Basel
  • Switzerland
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Aeschenvorstadt 36
  • 4051 Basel
  • Switzerland

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Matterhorn Biosciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Bankruptcy: Liquidation 27-Apr-2024 Completed Bankruptcy: Liquidation
2. Seed Round 05-Aug-2020 Completed Generating Revenue
1. University Spin-Out 01-Jan-2020 Completed Startup
To view Matterhorn Biosciences’s complete valuation and funding history, request access »

Matterhorn Biosciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Preference
To view Matterhorn Biosciences’s complete cap table history, request access »

Matterhorn Biosciences Patents

Matterhorn Biosciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2023001982-A1 Mr1 ligands and pharmaceutical compositions for immunomodulation Inactive 21-Jul-2021

Matterhorn Biosciences Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Matterhorn Biosciences FAQs

  • When was Matterhorn Biosciences founded?

    Matterhorn Biosciences was founded in 2020.

  • Where is Matterhorn Biosciences headquartered?

    Matterhorn Biosciences is headquartered in Basel, Switzerland.

  • What is the size of Matterhorn Biosciences?

    Matterhorn Biosciences has 41 total employees.

  • What industry is Matterhorn Biosciences in?

    Matterhorn Biosciences’s primary industry is Drug Discovery.

  • Is Matterhorn Biosciences a private or public company?

    Matterhorn Biosciences is a Private company.

  • What is Matterhorn Biosciences’s current revenue?

    The current revenue for Matterhorn Biosciences is .

  • How much funding has Matterhorn Biosciences raised over time?

    Matterhorn Biosciences has raised $30M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process